Marvel Biosciences (TSXV:MRVL) Debt-to-Asset : 7.81 (As of Jan. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Debt-to-Asset?

Marvel Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was C$0.00 Mil. Marvel Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was C$1.71 Mil. Marvel Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2025 was C$0.22 Mil. Marvel Biosciences's debt to asset for the quarter that ended in Jan. 2025 was 7.81.

Marvel Biosciences Debt-to-Asset Historical Data

The historical data trend for Marvel Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Debt-to-Asset Chart

Marvel Biosciences Annual Data

Trend

Jul20

Jul21

Jul22

Jul23

Jul24

Debt-to-Asset

1.49

3.48

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Debt-to-Asset	Get a 7-Day Free Trial														2.11	4.32	3.48	7.47	7.81

Competitive Comparison of Marvel Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Marvel Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Marvel Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Marvel Biosciences's Debt-to-Asset for the fiscal year that ended in Jul. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	1.71)	/	0.491
	=	3.48

Marvel Biosciences's Debt-to-Asset for the quarter that ended in Jan. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	1.71)	/	0.219
	=	7.81

Marvel Biosciences (TSXV:MRVL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Marvel Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

MBCOF:USA

Address

505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2

Website

https://www.marvelbiotechnology.com

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Executives